Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has expanded its oncology product portfolio to 13 products, with core products like Dabrushe (sintilimab injection) showing steady growth and new products contributing significantly to revenue [2] - The company has successfully entered the chronic disease commercialization sector, leveraging unmet needs and strong product competitiveness to drive growth [2] Group 2 - The company’s innovative pipeline focuses on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC), along with developments in metabolic and cardiovascular (CVM), autoimmune, and ophthalmology fields, which are making significant progress [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its global clinical development efforts [3]

Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, reflecting a year-on-year increase of over 60% [1] Group 1 - 2025 marks a milestone year for the company as product revenue surpasses RMB 10 billion, demonstrating the success of its "dual-driven and global innovation" strategy [2] - The company has expanded its oncology product portfolio to 13 products, with core products like Darbeshou® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [2] - The company has successfully entered the chronic disease commercialization sector, leveraging unmet needs and strong product competitiveness to drive growth [2] Group 2 - Key emerging drivers of revenue growth include Xinermy® (masitinib injection), Xinbile® (toripalimab injection), and Xinbimin® (teplizumab injection), which are experiencing accelerated market uptake [2] - Another important product, Xinmeiyue® (picanquizumab injection), received approval for market launch by the end of 2025 [2] - The company's performance in 2025 reaffirms its excellent commercialization capabilities and sustainable business development model [2] Group 3 - The company is making significant progress in its global innovation pipeline, focusing on next-generation immunotherapies (IO) and antibody-drug conjugates (ADC), as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - These advancements are expected to create additional growth opportunities and support the company's vision of becoming a leading international biopharmaceutical company [3]

Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has strengthened its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with core products like Darbeshou (Sintilimab injection) showing steady growth [2] - The company has successfully ventured into the chronic disease commercialization field, leveraging unmet needs and strong product competitiveness to drive growth, with key products like Xin'ermei (Masitide injection) and Xinbile (Torecilizumab injection) becoming significant revenue contributors [2] Group 2 - The company's global innovation strategy continues to make breakthroughs, focusing on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC) in oncology, as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its ongoing clinical development and strategic advantages in flexible layout and efficient execution [3]